ICU Medical (NASDAQ:ICUI) Updates FY 2025 Earnings Guidance

ICU Medical (NASDAQ:ICUI) issued an update on its FY 2025 earnings guidance on Thursday morning. The company provided earnings per share guidance of 6.550-7.250 for the period, compared to the consensus earnings per share estimate of 7.130. The company issued revenue guidance of -.

ICU Medical Price Performance

ICUI traded down $4.52 during midday trading on Thursday, hitting $149.75. 388,345 shares of the company traded hands, compared to its average volume of 201,601. The company has a current ratio of 2.29, a quick ratio of 1.03 and a debt-to-equity ratio of 0.75. The company has a market capitalization of $3.67 billion, a price-to-earnings ratio of -32.77 and a beta of 0.63. ICU Medical has a 52-week low of $93.36 and a 52-week high of $196.26. The business has a 50 day simple moving average of $160.70 and a two-hundred day simple moving average of $166.21.

ICU Medical (NASDAQ:ICUI) last issued its earnings results on Thursday, February 27th. The medical instruments supplier reported $1.72 EPS for the quarter, beating analysts’ consensus estimates of $1.48 by $0.24. ICU Medical had a negative net margin of 4.74% and a positive return on equity of 5.05%. On average, equities analysts forecast that ICU Medical will post 4.11 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities research analysts have recently commented on ICUI shares. StockNews.com upgraded shares of ICU Medical from a “hold” rating to a “buy” rating in a research report on Wednesday, November 20th. Jefferies Financial Group upgraded shares of ICU Medical from a “hold” rating to a “buy” rating and set a $200.00 price objective for the company in a research report on Wednesday, December 11th. Needham & Company LLC restated a “hold” rating on shares of ICU Medical in a research report on Wednesday, November 13th. Finally, KeyCorp raised their price objective on shares of ICU Medical from $198.00 to $209.00 and gave the stock an “overweight” rating in a research report on Wednesday, November 13th. One analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. According to data from MarketBeat.com, ICU Medical currently has a consensus rating of “Moderate Buy” and an average price target of $199.67.

Insider Buying and Selling at ICU Medical

In other ICU Medical news, CEO Vivek Jain sold 1,373 shares of ICU Medical stock in a transaction dated Thursday, January 2nd. The shares were sold at an average price of $155.48, for a total transaction of $213,474.04. Following the completion of the sale, the chief executive officer now directly owns 104,593 shares in the company, valued at $16,262,119.64. This trade represents a 1.30 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Company insiders own 6.70% of the company’s stock.

About ICU Medical

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.